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Abstract
Background: Carcinoma of the oral tongue (OTSCC) is the most common malignancy of the oral cavity, characterized
by frequent recurrence and poor survival. The last three decades has witnessed a change in the OTSCC epidemiological
profile, with increasing incidence in younger patients, females and never-smokers. Here, we sought to characterize the
OTSCC genomic landscape and to determine factors that may delineate the genetic basis of this disease, inform
prognosis and identify targets for therapeutic intervention.
Methods: Seventy-eight cases were subjected to whole-exome (n = 18) and targeted deep sequencing (n = 60).
Results: While the most common mutation was in TP53, the OTSCC genetic landscape differed from previously
described cohorts of patients with head and neck tumors: OTSCCs demonstrated frequent mutations in DST and RNF213,
while alterations in CDKN2A and NOTCH1 were significantly less frequent. Despite a lack of previously reported NOTCH1
mutations, integrated analysis showed enrichments of alterations affecting Notch signaling in OTSCC. Importantly, these
Notch pathway alterations were prognostic on multivariate analyses. A high proportion of OTSCCs also presented with
alterations in drug targetable and chromatin remodeling genes. Patients harboring mutations in actionable pathways
were more likely to succumb from recurrent disease compared with those who did not, suggesting that the former
should be considered for treatment with targeted compounds in future trials.
Conclusions: Our study defines the Asian OTSCC mutational landscape, highlighting the key role of Notch signaling in
oral tongue tumorigenesis. We also observed somatic mutations in multiple therapeutically relevant genes, which may
represent candidate drug targets in this highly lethal tumor type.
Background
Oral squamous cell carcinoma (OSCC) accounts for
270,000 new cancer cases and 145,000 deaths annually,
the majority of which occur in developing countries [1].
Of these, two-thirds are oral tongue squamous cell car-
cinoma (OTSCC) [2, 3]. Current treatment strategies
involve a multimodality approach involving surgery,
chemotherapy, and radiotherapy. Unfortunately, despite
advances in detection and treatment, 5-year overall
survival (OS) rates for OTSCC remain alarmingly low
[4]. Currently, for all cancers arising in the head and neck
[head and neck squamous cell carcinoma (HNSCC)], can-
cers of the tongue remain among the worst in terms of
prognosis [4].
OTSCC traditionally was thought to be a cancer afflict-
ing older males with longstanding exposure to tobacco
and alcohol. In recent decades, however, there appears to
have been a shift in epidemiology towards a higher pro-
portion of never-smokers and younger patients, with an
increase in incidence among women [5–9]. Although the
basis of this epidemiological trend remains elusive, what is
definitely worrisome is that the cancers arising in this
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‘atypical population’ tend to be more aggressive and re-
sistant to conventional treatment [6, 8, 9].
The expanding application of next-generation sequen-
cing technology to cancer has revolutionized our ability
to identify genetic alterations essential for carcinogenesis
and to uncover therapeutic vulnerabilities. Coupled with
the rapidly expanding array of therapeutic compounds
targeting key somatic oncogenic ‘driver’ alterations, these
technologies promise a new era for targeted therapy [10].
This approach has made significant headway in a number
of cancers, such as breast and lung carcinoma, where al-
terations in the EGFR/ERBB pathways proved to be the
main drivers that could be targeted with specific small
molecules [11, 12].
Unfortunately, it has been difficult to translate the
same success across to HNSCC. Recent large-scale gen-
ome sequencing efforts have validated TP53 as the com-
monest mutation in HNSCC, but have failed to identify
any single ‘oncogenic driver’ gene or family that is con-
ventionally targetable, although some studies are exam-
ining the possibility of targeting tumor suppressors
using synthetic lethal approaches [13–17]. Notably, the
majority of these publications, including The Cancer
Genome Atlas (TCGA), have focused on HNSCC as a
single entity [18]. However, epidemiological evidence
suggests that biological differences and clinical peculiar-
ities do exist between different head and neck sites, sub-
sites and populations affected by this disease [1, 19, 20].
For example, certain molecular alterations appear to be
present in higher frequencies or unique to certain sites/
subsites: these include PIK3CA mutations that are more
prevalent in human papillomavirus (HPV)-induced oro-
pharyngeal cancer, and alterations in USP9X, MLL4,
ARID2, UNC13C, and TRPM3 in gingiva-buccal cancers
[18, 21, 22]. Even within the oral cavity alone, the dis-
tinct clinical behaviors of tumors arising from the oral
tongue, buccal, alveolar, and hard palate suggests that
these should be examined as different and separate en-
tities [9]. Specifically, in the oral cavity, tumors arising
from the anterior tongue are known to be more infiltra-
tive and metastatic and hence have the poorest outcome
compared with tumors in other subsites [4, 23, 24].
Furthermore, it is now emerging that the mutation
spectrum of many malignancies can be strongly influ-
enced by ethnic background, encompassing population
genomic variations, environmental exposures, and life-
style practices [25–27]. For example, in a recent Inter-
national Cancer Genome Consortium (ICGC) analysis
of gingiva-buccal cancers, specific genetic changes
appeared to be unique to patient ethnicity (Indian) or
disease etiology (betel nut chewing) [22]. Taken collect-
ively, these findings raise the important need to con-
sider HNSCC not as one condition but as a spectrum
of different diseases, thus requiring genomic analysis of
specific cohorts that are well-defined with regards to
disease subsite and the at-risk patient population [28].
To date, the majority of previous genetic studies fo-
cused on OTSCC have been confined to single gene ana-
lysis or used limited gene panels, and thus have not
provided a comprehensive landscape [29, 30]. A recent
publication that examined the mutational spectra and
copy number variations of oral tongue tumors showed
that tumors from young patients and non-smokers ap-
pear to be genomically similar to those of older patients
and smokers [17, 28]. These data suggest that genomic
alterations are unable to account for the changing demo-
graphics in OTSCC. In this study, we set out to define
the mutational landscape of OTSCC in an Asian popula-
tion, with a secondary focus on identifying driver muta-
tions with a potential for therapeutic targeting. Our
objectives were to determine whether tumors arising
from the tongue had a distinct genetic landscape, if these
differences were population specific or correlated with
any epidemiological factors (e.g., gender), and to deter-
mine the proportion of alterations with therapeutic
potential.
Methods
Patients and bio-specimens
Patients were identified from an institutional database of
a consecutive series of patients treated at the National
Cancer Centre Singapore between 1998 and 2012. In-
cluded patients were confirmed to have a histological
diagnosis of squamous cell carcinoma involving the an-
terior tongue, with complete clinico-pathologic data and
fresh frozen tumor samples available, with primary sur-
gical treatment at the National Cancer Centre Singapore.
Only patients aged 21 years or above diagnosed with pri-
mary OTSCC and not previously treated were included
in the study. Treatment decisions were made in weekly
multi-disciplinary meetings and recorded prospectively.
All patients were treated with primary surgery followed
by adjuvant therapy, if applicable. Samples for 78 pa-
tients were retrieved from the Singhealth Tissue Reposi-
tory and tumor content confirmed to be greater than
50 % by a board-certified pathologist (TKL). For the
‘discovery set’, germline DNA from blood was used as a
reference for detecting somatic alterations. Medical re-
cords were reviewed for standard demographic data, risk
factors, clinical, radiological, and histo-pathologic infor-
mation, treatment parameters, and outcome of the
disease. Smoking was defined as use of tobacco, chew-
able or smoked, for at least 1 year continuously. Patient
characteristics are shown in Additional file 1.
Ethical issues
In accordance with the Helsinki Declaration of 1975,
standardized written consent for use of clinical material
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(which covers tumor tissue, blood, or other clinical spec-
imens) and clinico-pathologic data for research was ob-
tained at the time of surgical excision. Both this study
and the tissue collection/consent protocols have been
approved by the Singhealth Centralized Institutional
Review Board (CIRB 2007/438/B).
DNA extraction, library construction, exome capture, and
sequencing
Genomic DNA was isolated from tumor specimens and
blood samples using the DNeasy Blood and Tissue kit
(Qiagen, Crawley, UK) according to the manufacturer’s
instructions. Two micrograms of genomic DNA was
sheared to 200 bp using a Covaris E Series ultrasonic
solubilizer (Covaris Inc., Woburn, MA, USA) and after
adapter ligation the resultant library was subjected to
DNA capture using either the Agilent SureSelect Human
All Exon 50 MB V3 (Agilent, Santa Clara, CA, USA) or
a custom-designed capture library (SureSelect XT2
Target Enrichment System, Agilent) designed to capture
the coding sequences of 465 genes. Library construction
and DNA capture were carried out according to the
manufacturer’s instructions. The custom 465-gene Sure-
Select capture probes were designed using the Agilent
SureDesign package [31]. The concentration and size
distribution of the libraries were determined on an
Agilent Bioanalyzer DNA 1000 chip. Captured libraries
were sequenced on a HiSeq2000 platform (Illumina, San
Diego, CA, USA). The image analysis and base calling
were done using the Illumina pipeline (v.1.6) with de-
fault settings.
Sequence processing and variant calling
Read pairs were aligned to the National Center for
Biotechnology Information (NCBI) human reference
genome GRCh37 (hg19) using Burrows-Wheeler Aligner
(BWA) software [32]. PCR duplicates removal was done
using SAMTools [33]. After duplicate removal, the
Genome Analysis Tool Kit (GATK) [34] was used for base
quality score recalibration, local realignment around
indels, and variant calling. Partek Genomics Suite v.6.6
(Partek Inc., St. Louis, MO, USA) was also used to identify
somatic single nucleotide mutations in targeted exons.
To exclude common germline polymorphisms, the
detected variants were checked against dbSNP 138 [35],
1000 Genomes [36], and ExAC [37] databases. In the
discovery set, the variants detected in the matched nor-
mal controls were subtracted from variants detected in
the tumors. In the ‘prevalence set’, due to the absence of
matched normal controls, rare germline SNVs were dis-
carded using an in-house Southeast Asian normal exome
dataset, including 523 exomes (sgSNPG). For further
analysis, we restricted our attention to candidate som-
atic SNVs that were in the capture target and present
inside exons or at canonical splice sites, with a va-
riant depth ≥5 and depth in the normal sample ≥10.
Variants that passed this filtering were annotated using
several gene-transcript databases (Consensus CDS, RefSeq,
Ensembl and UCSC [38]). Amino acid changes were
determined based on the longest gene transcript. Somatic
nonsynonymous single-nucleotide mutations were ana-
lyzed using PolyPhen2 [39] in order to predict their
impact on the protein function. To identify significantly
mutated genes, the SMG test in the genome MuSiC
(Mutational Significance in Cancer) suite was used with
default parameters [40]. Microindels were detected using
GATK IndelGenotyperV2. For further analysis we only
considered microindels that were in a target and in an
exon or at a canonical splice site. Several filters were
applied to reduce false positives: we retained mic-
roindels that (1) were not in a simple repeat, (2) had
variant depth ≥5 with at least one read on each strand,
(3) had depth in the normal sample ≥10, (4) were con-
tained in ≥5 % of the reads, (5) had average base quality of
all bases inside the microindel and ±5 bases around the
microindel ≥25, (6) had an average number of mismatches
in the reads containing the microindel ≤4, and (7) had an
average fraction of mismatched bases in reads containing
the microindel ≤0.2. Candidate somatic alterations were
also assessed by visualizing sequencing data for each alter-
ation using the Integrative Genomics Viewer (IGV; version
2.3.25) [41]. The COSMIC database was used to annotate
known cancer variants. Raw sequence data have been
deposited at the European Genome-phenome Archive
[42], accession number [EGA:EGAS00001001329].
Sanger sequencing validation
To validate somatic mutations by Sanger sequencing, PCR
amplicons encompassing the candidate mutation sites
were sequenced in cancer tissues and their normal tissue
counterparts using the ABI PRISM BigDye Terminator
Cycle Sequencing Ready Reaction kit (Applied Biosystems,
Foster City, CA, USA) on an ABI 3730 xl DNA Analyzer
(Applied Biosystems). PCR primers for amplification and
sequencing were designed by targeting regions im-
mediately flanking the predicted variant using Primer3
software [43]. The chromatograms were analyzed using
the CodonCode Aligner software [44] and manual review.
Gene selection for targeted sequencing
For the target-exome sequencing, 465 protein-coding
genes were selected according to the following criteria: (a)
genes identified as somatically altered in the discovery set
based on occurrence in at least two samples (28 genes);
(b) genes identified as somatically altered in the discovery
set based on occurrence in at least one sample, but har-
boring single-nucleotide variations (SNVs) called by both
caller algorithms, GATK and PGS (164 genes); (c) genes
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described as frequently altered in head and neck tumors
in earlier published literature [13, 14] (45 genes); (d) genes
with significant mutation frequency across 279 HNSCC
tumors present in TCGA dataset (42 genes); and (e) rec-
ognized cancer genes included in the Ion AmpliSeq™
Comprehensive Cancer Panel (Life Technologies) (186
genes) (Additional file 2).
Statistical analyses
Statistical analysis was performed using the statistical
software SPSS 19.0 for Windows (IBM, New York, NY,
USA). In order to assess the association between the
anatomical and pathological variables of patients and the
molecular findings in the tumor samples, the chi-square
or Fisher’s exact tests were performed, as appropriate.
Mutational frequency differences between the OTSCC
and TCGA data were assessed using chi-square test,
followed by the Benjamini-Hochberg procedure for mul-
tiple testing corrections. Survival curves were calculated
by the Kaplan-Meier method and differences between
groups were compared using the log-rank test. OS was
measured as the time interval between the date of the
initial treatment for the primary tumor and the date of
the last follow-up or death, while disease-free survival
(DFS) was defined as the time interval between the date
of initial treatment and the date of the diagnosis of the
first recurrence. For evaluation of the independent con-
tribution of significant clinical and molecular variables
on DFS or OS, all factors with significance in Kaplan-
Meier analysis (P ≤ 0.2) were tested in the multivariate
analyses using the Cox proportional hazard model. Re-
sults were calculated with 95 % confidence intervals
(CIs). For all analysis we considered statistical sig-
nificance when P value < 0.05. In the pathway analysis,
the P values were calculated by Gene Set Enrichment
Analysis (GSEA) algorithm by estimating the hypergeo-
metric distribution of overlapping genes over all genes
in the gene universe.
URLs
UCSC Genome Bioinformatics [38], CodonCode Aligner
software [44], dbSNP [45], 1000 Genomes Project [46],
Exome Variant Server [47], COSMIC [48], ExAC data-
base [37], cBioPortal for Cancer Genomics [49], MSigDB
pathways database [50], Genomics of Drug Sensitivity in
Cancer [51], Clinical trials database [52], Drugs ap-
proved by US Food and Drug Administration (FDA)
[53], European Genome-phenome Archive [42].
Results
Patient characteristics
Eighteen OTSCC patient tumor and matched blood sam-
ples were used for the discovery set, and 60 tumor sam-
ples were used in the prevalence set (clinico-pathologic
data for both cohorts is shown in Additional file 1). The
prevalence set was used for all subsequent clinical cor-
relations. In the latter cohort, approximately half (51.7 %;
n = 31) were smokers, 63.3 % (n = 38) were males, with a
median age of 55.5 years (range 21–89 years). All patients
in the prevalence cohort underwent surgery as the
primary modality of treatment, and 26 (43.3 %) received
adjuvant radiation or chemo-radiation therapy. Approxi-
mately half presented with locally advanced disease (pT3/
T4, 48.3 %, n = 29) and had pathologic evidence of nodal
metastasis (pN+, 46.7 %, n = 28) at presentation. Patients
were followed up for a median of 36 months (range 1–190
months). During this time period, there were 17 (28.3 %)
recurrences and 13 (21.7 %) deaths.
Overview of OTSCC somatic mutation profile
To identify somatic mutations, we performed whole-
exome capture and massively parallel DNA sequencing
on paired DNA samples (tumor and matched white
blood cells) from 18 OTSCCs (discovery set). From each
sample, we sequenced around 16 billion bases, resulting
in an average 93-fold coverage of each base in the tar-
geted regions (range 70–115), with 94 % of DNA se-
quences being covered sufficiently (≥10×) for confident
variant calling (Additional file 3).
Overall, 1,092 nonsynonymous somatic variations af-
fecting 750 genes were detected, of which 992 were som-
atic SNVs and the remaining were somatic insertions or
deletions (indels) (Additional file 4). The co-mutation
plot for the discovery set is provided in Additional file 5.
Of the single-nucleotide substitutions, 888 (81.3 %) were
predicted to be missense mutations, 68 (6.2 %) nonsense
mutations, and 36 (3.4 %) splice site mutations. The
number of variants (SNVs and indels) per patient ranged
from 11 to 105, with a mean of 61 mutations per sample,
similar to previous oral cavity whole-exome sequencing
studies (ranging from 29 to 85) [22, 28]. The alterations
were verified manually using IGV. Subsequent technical
validation by Sanger sequencing confirmed the presence
of mutations in 28 genes (28/29, true-positive rate of
96.6 %), demonstrating that the algorithms used (GATK
and PGS) for identifying mutations were reliable. Over-
all, the whole-exome sequencing of the discovery set in-
dicated 28 genes harboring somatic coding mutations in
two or more oral tongue tumors (a list of these 28 genes
is presented in Additional file 6).
Nucleotide sequence contexts of somatic mutations
can be indicative of specific mutagenesis mechanisms
occurring in tumor cells [54–56]. Analyzing synonymous
and non-synonymous alterations, we observed elevated
rates of C > T transitions, particularly at CpG positions,
consistent with deamination of 5-methyl-cytosine to ura-
cil by APOBEC or other endogenous processes. C > G
mutations were also common (Additional file 7). We
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visually examined the somatic mutation spectra of the
18 exome-sequenced tumors and performed principal
component analysis to search for possible systematic dif-
ferences in spectra according to several clinical factors:
age, smoking status, gender, HPV status, ethnicity, and
recurrence. These analyses did not suggest any sys-
tematic differences according to any of these categories
(Additional file 6; see “Discussion”).
Copy number variant analyses were performed as pre-
viously described [57]. The results are presented in
Additional files 8, 9, and 10. We identified 30 amplified
regions and 56 regions with recurrent deletions in the
discovery set. Focal amplifications in chromosome 7 har-
boring the MET oncogene were seen in 7 of 18 samples,
while deletions were commonly seen on chromosome 3
(9/18 samples), involving VHL, SETD2, PBRM1, MLH1,
and BAP1. All regions of gains and losses, with their
corresponding tumor-associated genes are indicated in
Additional files 8 and 9. There were no correlations be-
tween copy number variants and smoking status, age,
gender, ethnicity, or recurrence.
Evaluating the frequency and distribution of somatic
mutations by target sequencing
To further investigate the precise frequency and distribu-
tion of somatic mutations in an expanded OTSCC cohort,
we designed a panel with 465 genes including (a) the 28
candidate genes frequently mutated in the discovery set,
(b) genes previously described as frequently mutated in
HNSCC [13, 14], and (c) recognized cancer genes that
were manually curated (a list of all genes included in the
target panel is presented in Additional file 10). These
genes were sequenced in a prevalence set of 60 treatment-
naive snap-frozen OTSCC specimens by targeted sequen-
cing with an average depth of 136× (Additional file 11).
For the prevalence set, we used a consecutive patient
series treated in a standardized manner in order to make
meaningful conclusions on epidemiology and outcome,
and only tumor samples were available for this cohort
[58]. Therefore, an alternative strategy to discriminate
germline SNVs in the absence of normal tissue DNA was
adopted, following previously described studies [59, 60].
We created a high-fidelity tumor-only analysis pipeline that
relied on two steps. First, we excluded variants found in
either public databases of germline SNVs [dbSNP (build
132), 1000 Genomes, and EVS (6500-SI-V2)] [35, 36, 47]
or in an in-house database of germline SNVs drawn from
523 normal Asian exomes. We initially also planned to ex-
clude variants described in the beta version of the ExAC
database, but preliminary tests showed that this filtering
steps removes a significant proportion of the TP53 alter-
ations in our cohorts (23 % discovery set and 22 % preva-
lence set). Furthermore, the examination of the TCGA
data for HNSCC also revealed that 22 % of the TP53
mutations described there were also present in the ExAC
database, with a significant proportion of damaging mis-
sense mutations. Given these findings, we did not utilize
the ExAC database in the final analysis. Variants present in
the COSMIC database (v.52) were kept regardless of their
match in the other databases, because dbSNP in particular
contains some known oncogenic somatic mutations. Sec-
ond, we excluded variants with allele frequencies >0.41.
The rationale for this criterion is that somatic mutations
usually present with variant read proportions substantially
less than 0.5 in next-generation sequencing data, due to
admixture of genomes from non-malignant cells in a
tumor sample. By contrast, germline variants have read
proportions of either 1 (for homozygous variants) or ~0.5
(for heterozygous variants) in regions where the tumor
genome is diploid. We note that copy number gains or
losses in tumor genomes may alter the expected variant
read proportions of germline variants, so this two-step ap-
proach will not always exclude germline variants. Con-
versely, genomic copy number gains may sometimes cause
somatic mutation to have read proportions greater than
0.5, so this two-step approach sometimes incorrectly ex-
cludes somatic mutations. As discussed below, we esti-
mated the accuracy of this approach in a set of HNSCCs
with matched normal DNA.
To validate this two-step tumor-only filtering protocol
and to verify the extent to which it would retain rare
germline alterations amidst bona fide somatic mutations,
we applied it to both the discovery set and an independ-
ent cohort of 16 HNSCC exomes for which normal
matched controls were available. For the discovery set,
this algorithm showed a high degree of reliability and ac-
curacy with a positive predictive value (PPV) of 92 %
and negative predictive value (NPV) of 96 % (with 89 %
sensitivity and 97 % specificity). Further validation of
this tumor-only protocol in an independent cohort of 16
non-subsite specific HNSCC samples also showed good
reproducibility with PPV of 94 % and NPV of 89 % (with
73 % sensitivity and 98 % specificity). These control ana-
lyses support the notion that our tumor-only filtering
protocol does not lead to excessive numbers of germline
variants miscalled as somatic mutations.
After applying the tumor-only filtering protocol to the
prevalence set, 380 genes were detected as harboring
SNVs or indels. All mutations identified in the preva-
lence set are shown in Additional file 12. Unsurprisingly,
the most prevalent genetic alteration detected in this
cohort comprised a broad spectrum of TP53 mutations
(38.3 %). Other genes recurrently mutated include DST
(26.7 %), RNF213 (16.7 %), USH2A (16.7 %), FAT1
(16.7 %), MLL3/KMT2C (16.7 %), COL6A6 (15.0 %),
ZFHX4 (15.0 %), PLEC (15.0 %), and SYNE1 (13.3 %)
(Fig. 1). We examined expression levels of these ten genes
using HNSCC RNA-seq data from TCGA and our own
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previously published microarray data [61], both of which
confirm that the genes listed here are known to be
expressed in OTSCC (data not shown).
This pattern of Asian OTSCC genetic mutations was
compared with the profile of 172 exomes from oral
cavity tumors available from TCGA (OC-TCGA) [48].
One major caveat to this comparison is that there are fun-
damental differences between the two cohorts examined
here in terms of tumor site (tongue versus oral cavity), dis-
ease stage, ethnicity (Asian versus North American) and
environmental exposure. Single gene comparisons showed
that mutation frequencies of the following genes were
higher in Asian OTSCCs compared with OC-TCGA: DST
(P < 0.001), RNF213 (P = 0.012), COL6A6 (P = 0.049) and
ZFHX4 (P = 0.031). Even after multiple hypothesis correc-
tion, mutation frequencies remained higher in Asian
OTSCCs for DST (P = 0.001) and RNF213 (P = 0.033)
(Fig. 2). In contrast, OC-TCGAs exhibited more frequent
mutations in TP53 (P < 0.001), CDKN2A (P = 0.005), and
NOTCH1 (P = 0.019). Critically, no significant differences
were observed in the mutation rates of many other genes
frequently mutated in both cohorts (CASP8, CDH10,
EP300, FAT1, MLL2/KMT2D, MLL3/KMT2C, NSD1,
PIK3CA, PLEC, SYNE1, and USH2A). These similarities in
mutation frequency in the latter genes provide a sound
validation of and positive control for our methodology, for
both the experimental approach (tumor content, library
creation, and sequencing) and bioinformatics pipeline.
Analysis of significantly altered pathways
Pathway analysis was performed to examine the associ-
ation between mutation profiles and core canonical
pathways in Asian OTSCC, using either the MSigDB
pathways database [62] or compared with manually cu-
rated cancer-related pathways [63, 64]. Putative cancer-
related pathways achieving statistical significance, as
determined by GSEA, are listed in Additional file 13.
Among the most prominently mutated pathways were
the epidermal growth factor receptor (EGFR), ERRB,
mitogen-activated protein kinase (MAPK), and NOTCH
signaling pathways, as well as adherens junction and
focal adhesion pathways (Fig. 3; Additional file 14).
Overall, 55 % of the OTSCC samples had mutations in
at least one gene affecting the MAPK pathway, while
EGFR, Notch, and ERBB signaling families where modi-
fied in 52 %, 32 % and 23 % of cases, respectively. Genes
involved in cell junction organization and focal adhesion
pathways were mutated in 22 % and 53 % of OTSCC
cases, respectively. Other core canonical signaling path-
ways frequently found mutated in OTSCC included
Fig. 1 Mutation plot summary of 60 oral tongue squamous cell carcinoma patients showing frequently mutated genes. The top plot shows the
key clinical parameters, below which the mutation status of the recurrently mutated genes for each tumor is indicated. Somatic mutations are
colored according to functional class according to the legend below the plot. Prevalence is indicated as number of mutations in the graph on
the right and mutational frequency is given on the left of the mutation plot
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mammalian target of rapamycin (mTOR), transforming
growth factor β–SMAD, chromatin remodeling genes,
KIT, β-catenin and apoptosis, many of which may have
therapeutic implications. Correlations between significantly
altered pathways and clinical characteristic/outcomes are
presented in Additional file 15.
Notch pathway mutations
As stated above, we found the Notch pathway to be
altered in a high proportion of the Asian OTSCCs.
However, classical single-gene NOTCH1 mutations, previ-
ously reported in other studies, were notably absent from
our cohort (only three cases have NOTCH1 mutations).
Nevertheless, pathway analyses demonstrated that the
Notch signaling pathway was altered in OTSCC in the
same proportion as previously reported for HNSCC
[14] or detected in oral cavity tumors and HNSCC by
TCGA (Fig. 4). Genes recurrently altered in this path-
way include AR, ARNT, EP300, CREBBP, JAK2, JAK3
NCOA1, NOTCH2, NOTCH3, and PARP1. In total, the
A
B
Fig. 2 The frequency of commonly mutated genes in the current cohort of oral tongue squamous cell carcinoma (OTSCC) compared with oral
cavity squamous cell carcinoma from TCGA (OC-TCGA). a The most frequently mutated genes in the OTSCC cohort. b The most frequently
mutated genes in the OC-TCGA cohort. Significance is determined by multiple hypothesis testing using chi-square test, followed by the
Benjamini-Hochberg procedure. NS not significant
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Notch signaling pathway was altered in 32 % (19/60) of
the OTSCC cases, with all somatic events following a
mutually exclusive pattern (Fig. 4).
Interestingly, mutations in the Notch signaling pathway
were enriched in women compared with men (P = 0.04;
Additional file 15). More importantly, a striking differ-
ence in DFS was observed between OTSCC cases
with mutations in the Notch pathway compared with
those without, where the former had significantly poorer
outcomes (P = 0.005; Fig. 4; Additional file 13). Based on
multivariate models that included clinico-pathologic cor-
relates associated with prognosis (age, tobacco consump-
tion, N stage and extra-capsular spread), modifications in
the Notch pathway remained an independent predictor
for DFS. Patients with Notch pathway mutations were 3.3
times more likely to die with recurrent disease compared
with those who did not have these alterations [p = 0.016,
hazard ratio (HR) = 3.3, 95 % CI = 1.24–8.94; Fig. 4].
Analysis of TCGA data for oral cavity suggests a similar
trend towards poorer OS in patients with alterations in
this pathway, however this was not statistically significant
(p = 0.13; data not shown).
Gene expression microarray data were available for a
limited number of these samples: Notch pathway altered
(n = 9) versus Notch pathway wild type (n = 21) [61].
GSEA analysis of gene expression confirmed that the pres-
ence or absence of these somatic events resulted in signifi-
cant alteration of two Notch associated pathways (Nguyen
Notch1 Targets DN, p = 0.004; PID Notch pathway,
p = 0.011), confirming that these alterations truly modu-
late Notch signaling (Additional file 16). These orthogonal
data suggest that the Notch pathway is modulated as pre-
dicted in the cases with mutations in Notch pathway.
Chromatin remodeling gene family
There has been significant interest in the role of chroma-
tin remodeling enzymes in a range of cancers, and exam-
ination of this gene set revealed alterations in 42 % of the
OTSCC cohort, similar to data from TCGA for the oral
cavity (42 %) and for all HNSCC (47 %) (Fig. 5). Chro-
matin remodeling genes frequently altered in OTSCC
included CREBBP, EP300, KAT6A, MLL/KMT2A, MLL2/
KMT2D, MLL3/KMT2C, NCOA1, NSD1, SETD2, and
WHSC1. Moreover, most of the mutations in this gene
family were mutually exclusive, especially mutations af-
fecting the MLL family of histone methyltransferases
(Fig. 5). Mutations affecting chromatin remodeling
genes were significantly more frequent in older patients
(p = 0.03; Additional file 15) and patients with mutations
have significantly poorer DFS compared with those who
A
C
B
D
Fig. 3 Pathway map showing molecular circuits implicated in OTSCC. a EGFR and HER2. b Adherens junction. c NOTCH. d Focal adhesion.
Numbers in each box represent the percentage of tumors harboring mutations in the respective gene
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did not (p = 0.01; Fig. 5). Based on multivariate models,
modifications in this gene set remained an independent
predictor for DFS. Patients with mutations in this pathway
were 3.3 times more likely to die with recurrent disease
compared with those who did not have these alterations
(p = 0.03, HR = 3.3, 95 % CI = 1.12–9.55; Fig. 5). Again,
analysis of TCGA data for tongue cancers suggests a simi-
lar trend towards poorer OS in patients with alterations in
this pathway, although this was not statistically significant
(P = 0.11; data not shown).
Remarkably, multivariate analysis including both the
Notch pathway and chromatin remodeling genes as vari-
ables showed that alterations in the Notch pathway
remained as an independent predictor of recurrence.
Patients harboring mutations in at least one member of
this signaling pathway were 2.9 times more likely to de-
velop recurrence and die (P = 0.037, HR = 2.9, 95 % CI =
1.07–7.73; Fig. 5). Furthermore, this same multivariate
model also revealed a tendency towards to significance for
the presence of mutations in chromatin remodeling genes
(P = 0.057, HR = 2.9, 95 % CI = 0.97–8.91; Fig. 5).
Analysis of significantly altered actionable mutations
Finally, the mutation data were also used to characterize
alterations in drug targetable genes. In this analysis,
manually curated gene sets were assembled based on
genes known to have similar functions/pathways, gene
families, or overlapping cross-sensitivity to available tar-
geted compounds [53, 65, 66]. This group of 20 genes
included receptor tyrosine kinases, ERBB, JAK-STAT,
MAPK-AKT, and phosphoinositide 3-kinase (PI3K) sig-
naling, for which therapeutic agents are currently in
clinical use or available in the trial setting. Based on this
list, 50 % of OTSCC samples harbored modifications in
A
D E
B C
Fig. 4 a Co-mutation map showing alterations in genes involved in the Notch pathway in 19 (32 %) oral tongue squamous cell carcinoma
(OTSCC) samples. Gene names and mutation rates are as indicated on either side of the plot, while the type of mutation follows the legend
below. b, c Comparison between OTSCC, oral cavity cohort from TCGA (OC-TCGA) and entire head and neck cohort of TCGA (HN-TCGA) for
NOTCH1 mutation frequency and alterations in the entire Notch pathway (11 genes), respectively. P value based on t-test as indicated if significant
or NS if not significant. d Kaplan-Meier plot showing DFS estimates according to the mutational status of the Notch pathway. P value is based on
log-rank test. e Results of multivariate analysis of selected prognostic factors for DFS in OTSCC by Cox proportional hazards model. HR hazard ratio
Vettore et al. Genome Medicine  (2015) 7:98 Page 9 of 15
at least one of these genes, and the majority were mutu-
ally exclusive (Fig. 6). The majority of the PIK3CA muta-
tions (four out of five) are known to be activating
mutations, while about half the mutations in the ERBB
family of genes (three out of six) occur in regions that
affect signaling (extracellular domain or tyrosine kinase
domain) [30, 67]. Based on Polyphen2 analysis, a signifi-
cant proportion of the other mutations in this set of
‘druggable’ genes are predicted to be damaging to the re-
spective protein function. Of note, the frequency of
these ‘druggable mutations’ is significantly higher in
OTSCC compared with that detected in the oral cavity
tumor exomes analyzed by TCGA (P = 0.020; Fig. 6).
Discussion
To date, most cancer genome studies on OSCC have
regarded this entity as a homogenous disease. However,
differences in biological behavior already hint that OSCC is
not a uniform condition [4, 9, 20], likely requiring dissec-
tion by populations affected, anatomic subsite and disease
etiology [22, 25, 27, 30]. This population/subsite/etiology-
based approach requires rigorous sample collection and
A
C
B
E
D
Fig. 5 a Co-mutation map showing alterations in genes involved in chromatin remodeling in 25 (42 %) oral tongue squamous cell carcinoma
(OTSCC) samples. Gene names and mutation rates are as indicated on either side of the plot, while the type of mutation follows the legend
below. b Comparison between OTSCC, the oral cavity cohort from TCGA (OC-TCGA) and the entire head and neck cohort of TCGA (HN-TCGA) for
frequency of genetic alterations in ten chromatin remodeling genes. P value based on t-test; NS not significant. c Kaplan-Meier plot showing DFS
estimates according to the mutational status of the chromatin remodeling family. P value is based on log-rank test. d, e Results of multivariate
analysis of selected prognostic factors for DFS in OTSCC by Cox proportional hazards model. HR hazard ratio
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exclusion of a significant number of cases that do not fit
the selection criteria. One of the first papers that used this
approach was the Indian ICGC group, who used exome
analysis for gingiva-buccal oral squamous cell carcinoma
(OSCC-GB). In this study, apart from detecting mutations
in genes previously associated with HNSCC (TP53,
NOTCH1, FAT1, and CASP8), they also identified recur-
ring alterations in genes specific to this disease (USP9X,
MLL4/KMT2B, ARID2, UNC13C, and TRPM3) [22].
In a similar fashion, our study focused on the mutational
landscape of squamous cell cancers arising from the single
subsite of oral (or anterior) tongue in a South-East Asian
population (OTSCC). More importantly, as this cohort of
patients was treated in a uniform manner at a single tertiary
institution, data from this study can also be used to draw
meaningful conclusions based on clinical correlates. Our
patient cohort exhibits several features that are representa-
tive of the evolution of this disease in Asia. First, there is an
almost equal proportion of smokers and non-smokers. Sec-
ond, the male:female ratio is approaching equivalence.
Third, the median age of disease has been declining over
the past three decades and is now around 55 years.
Reassuringly, mutational analysis of our OTSCC cohort
identified frequent nucleotide alterations in SYNE1, FAT1,
MLL2/KMT2A, MLL3/KMT2C, PIK3CA, and CASP8 at
similar frequencies reported by TCGA and ICGC. However,
there were significantly fewer mutations in TP53, NOTCH1,
and CDKN2A. Mutations in the RAS genes were extremely
infrequent (HRAS, n = 1/60, with no mutations in KRAS
and NRAS) and mutations in EGFR notably absent. In
contrast, several less well-characterized genes (DST and
RNF213) were mutated at higher rates in Asian OTSCC
than previously reported. Most of the unique genes de-
tected here were also not seen in the ICGC study, which
focused on an Indian population with tobacco- and betel
nut-associated OSCC-GB, reinforcing the need to carry out
similar studies in different populations. Indeed, we
hypothesize that the unique genetic alterations in both
studies can be attributable to the etiology of disease,
differences in the (Asian) population examined or the dis-
tinct biological features of the disease subsites (in this case
oral tongue). As predicted, these genetic alterations also
differed from HPV-driven cancers involving the base of
tongue, which had a higher frequency of activating muta-
tions in PIK3CA, with loss of TRAF3 and amplification of
E2F1 [18]. In a similar vein, patterns attributable to
etiology and specific populations have been observed for
other cancer types [27].
The reason for this changing epidemiology in a disease
(OTSCC) classically seen in older, male smokers remains
unknown, and one of the major objectives of this study
was to determine the genetic basis for this ‘emerging
phenotype’. Our analysis of OTSCC found no specific
mutations unique to younger patients or non-smokers,
A B
Fig. 6 a Co-mutation map showing alterations in drug targetable genes in 30 (50 %) oral tongue squamous cell carcinoma (OTSCC) samples with
gene names indicated on the left. b Comparison between OTSCC and oral cavity cohort from TCGA (OC-TCGA) for frequency of genetic alterations
in 20 drug targetable genes. P value based on t-test
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although there was a tendency towards more frequent
mutations in MLL2/KMT2A and PIK3CA in older pa-
tients. Moreover, the mutational signature in our cohort
did not reveal a tobacco-induced signature in OTSCC
cases grouped by age (young versus old) or by smoking
status, which is similar to findings by Pickering et al.
[28]. The latter recently reported whole-exome sequen-
cing analysis of two independent cohorts of tongue tu-
mors and found that mutational spectrum were similar
between young and old patients. Further, they also observed
that the types of base changes observed in the young cohort
were similar to those in the old cohort even though they
differed in smoking history, and no smoking signature
could also be found in OTSCC. These findings, now sup-
ported by two independent studies, suggests that tobacco
smoke, despite being an established risk factor for OTSCC,
may act primarily as a tumor promoter while having only a
minor impact on the initiation of tongue cancers [68].
Analysis of the OTSCC data at the gene set level pro-
vided valuable insights into pathways that potentially drive
OTSCC carcinogenesis. We were initially surprised that
NOTCH1 mutations were relatively infrequent in this
cohort, although one previous study in esophageal squa-
mous cell cancer had shown that NOTCH1 mutations are
uncommon in Asian patients compared with matched
Caucasian populations [69]. However, pathway analysis
confirmed that the Notch pathway was affected in a third
of our OTSCC cases by mutations that were mutually
exclusive, distributed across 11 distinct genes along the
pathway. These alterations were more common in women,
and of concern, they conferred a poorer prognosis in these
patients regardless of other factors or mutations, even on
multivariate analysis. The role of Notch as a tumor sup-
pressor pathway in OSCC has been suggested by several
studies [13, 14, 70]. Activated NOTCH1 has an anti-
proliferative effect in tongue tumor cells through down-
regulation of Wnt/β-catenin signaling, inducing apoptosis
and cell cycle arrest [71]. Furthermore, in a tongue cancer
model using mouse xenografts, the presence of NOTCH1
caused a dramatic reduction in tumor size compared with
tumors in which this gene was absent [17]. This apparent
discordance between infrequent NOTCH1 mutations per
se and a still defective Notch pathway through other gene
mutations in 32 % of OTSCC patients highlights the im-
portance of deregulating the Notch-driven epithelial cell
differentiation program in OTSCC through a range of
convergent targets.
Analyses of the chromatin remodeling gene family led
to similar conclusions. Interestingly, we observed a signifi-
cantly higher frequency of MLL3/KMT2C mutations
(16 %) in our cohort compared with mutations in the MLL
homologs MLL2/KMT2A in OC-TCGA (Western/predom-
inantly Caucasian population) [21] and in MLL4/KMT2D
in OSCC-GB [22]. Damaging mutations in MLL2/KMT2A
were more frequently identified in smokers in our cohort,
while the mutations in MLL4/KMT2D seem to be unique
to the Indian population studied by the ICGC [22]. The
higher frequency of MLL3/KMT2C mutations in our co-
hort may therefore be a phenomenon associated with
never-smoker OTSCC populations, and represents an-
other example of convergent evolution on a critical path-
way in OTSCC carcinogenesis.
Despite advances in technology, clinical outcomes have
not changed significantly over the past three decades for
OSCC. However, analysis of our cohort showed that at
least half of the patients harbored potentially targetable
mutations in signal transduction pathways, where targeted
compounds are already available. These results have several
important implications. Firstly, the mutation frequencies of
these genes in our population were significantly higher
than in previously reported studies, and this pattern should
therefore be taken into consideration in future trial designs.
Second, previous pessimism regarding the low occurrence
of sensitizing mutations in HNSCC should not be trans-
lated to any cohort until similar studies have been con-
ducted in this population/subsite/etiology-based approach.
Interestingly, there was a similar conclusion by the ICGC
group regarding OSCC-GB [22], who also similarly identi-
fied higher rates of potentially actionable mutations.
Beyond OTSCC, our study is also notable from a tech-
nical standpoint. To date, most cancer sequencing studies
have utilized tumor and normal matched pairs to distin-
guish de novo somatic mutations from existing germline
variants. In this study, we needed to obtain tumor repre-
sentation from a consecutive series of patients presenting
with tongue cancer, treated in a standardized manner with
clinic-pathologic and outcome data available, with no bias
in patient selection (prevalence set), to enable robust
clinico-pathological analysis. In this process, however, it
was not possible to obtain matched normal blood from
every patient in this prevalence set. This is a very common
scenario encountered in the translational research domain,
motivating the need to develop approaches to identify
somatic mutations in the absence of matched normal
controls. In our study, we addressed this challenge by
using, in addition to commonly used pipelines (e.g., 1000
Genomes, dbSNP, EVS), a locally assembled 523-patient
normal sample dataset to discriminate the germline SNVs.
One major concern was that this approach may not re-
move all rare germline alterations, erroneously classifying
these as somatic variations. To test the validity of this
approach, we determined the PPV, NPV, specificity, and
sensitivity of the filtering algorithm by applying the
tumor-only filtering protocol on the discovery set as well
as an independent cohort of HNSCC cases (comprising 16
tumor–normal matched pairs). The data for the discovery
set show that the methodology was extremely reliable,
with PPV and NPV over 90 %. Even after correcting for
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these accuracy data, the differences observed between our
cohort and TCGA remains significant. Further validation
of this approach can be inferred from the fact that we
found similar frequencies of mutations in a number of
genes previously detected by TCGA, including USH2A,
FAT1, PLEC, SYNE1, PIK3CA, MLL2/KMT2A, MLL3/
KMT2C, CASP8 COL6A6, and ZFHX4. There are a few
other studies in the literature where ‘tumor-only’ proto-
cols have been used. In a study conducted at the Sanger
Centre, investigators were able to identify base substitu-
tions and small insertions/deletions in the exome data
from 738 patients with myelodysplastic syndrome by com-
parison against one unmatched normal sample [59]. How-
ever, no data were presented on the accuracy of this
approach. Along the same line, a Japanese study identified
mutations in a cohort of 97 Japanese lung adenocarcin-
oma patients by filtering out germline variants present in
an external exome dataset composite by 217 normal con-
trol exomes from individuals with the same ethnic back-
ground [60]. The latter study reported accuracy rates of
64 %, establishing the validity of this approach. It is likely
that the accuracy rates for any tumor-only pipeline will
improve with increasing numbers of control/normal
sample data from which germline alterations can be sub-
tracted, and more importantly represent the same popula-
tion distribution in which the primary analysis is carried
out. The latter approach likely accounts for the accuracy
of our approach, which focused on the same patient popu-
lation. It is likely that with increasing numbers of normal
samples deposited into ‘open source’ databases like ExAC,
these algorithms can be further refined. Furthermore, the
availability of these databases and algorithms allow future
studies to proceed with retrospective sample collections,
regardless of matched normal samples, at half the cost for
sequencing. This approach also obviates the issue of deal-
ing with patient germline data and the inherent ethical
dilemma that this generates.
Conclusions
The present study identified genomic alterations enriched
in pathways that are specific to OTSCC. Of note, muta-
tions in genes in the Notch pathway and the chromatin
remodeling family were associated with poor prognosis in
individuals with oral tongue tumors. OTSCC is a fre-
quently lethal cancer with few effective therapeutic op-
tions. Despite the genomic alterations previously observed
in different HNSCCs, no new therapeutic targets have
been identified, and, therefore, surgery, radiation, and cis-
platin still remain as standard therapy for the disease. To
our knowledge, this is the first study identifying targetable
alterations in a high proportion of OTSCCs. This finding
is important with respect to the development of novel ap-
proaches to patient treatment, which could be used in
combination with standard therapy.
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